| Name | Company | P/L % | MPV |
|
|---|---|---|---|---|
| Lord Glendonbrook |
|
Stryker / NYQ:SYK | 374.86% | £332,404.21 |
| Lord Glendonbrook |
|
Abbott Laboratories / NYQ:ABT | 266.02% | £256,215.13 |
| Lord Sassoon |
|
Abbott Laboratories / NYQ:ABT | 181.09% | £196,765.95 |
| Lord Grabiner |
|
Boston Scientific / NYQ:BSX | 138.22% | £166,757.37** |
| Baroness Noakes |
|
Smith & Nephew / NYQ:SNN | 52.14% | £106,499.44 |
| Lord Glendonbrook |
|
Smith & Nephew / NYQ:SNN | 41.21% | £98,845.20 |
| Lord Mance |
|
Stryker / NYQ:SYK | 19.87% | £83,910.91 |
| Lord Glendonbrook |
|
Medtronic / NYQ:MDT | 10.66% | £77,463.33** |
| Lord Howard of Rising |
|
Ekf Diagnostics / LSE:EKF.L | 0.96% | £70,671.16 |
| Lord Londesborough |
|
Abbott Laboratories / NYQ:ABT | -15.02% | £59,489.07 |
| Lord Sassoon |
|
Medtronic / NYQ:MDT | -16.85% | £58,204.83 |
| Lord Glendonbrook |
|
Align Technology / NMS:ALGN | -30.35% | £48,755.80 |
| Lord Kakkar | Cyte / NMS:CTKB | -55.35% | £31,251.50** | |
| Lord Browne of Madingley | Allurion / NYQ:ALUR | -76.74% | £16,283.99 |